Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment Amylyx Pharmaceuticals NASDAQ...
Topics
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
Related QATS news
- Clorox, General Mills, and Constellation Brands Are Down Between 22% and 33%. Here's the Stock to Bu...
- Berkshire Hathaway Is Buying Up Shares of This Beaten-Down Stock. Should You Invest Too? From Sept....
- History Says Coca-Cola Stock Holds Up When the S&P 500 Falls Since 1980, the S&P 500 has logged a n...
- NuScale vs. Oklo vs. GE Vernova: Ranking 3 Nuclear Stocks By Backlog, Not Hype. These stocks are be...